+91.3%
GLD vs MRNA
-27.3%
+118.6%
-34.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.7% | -2.2% | -1.5% | -3.6% |
| 7D | -9.2% | -12.7% | +3.5% | -8.8% |
| 30D | -14.8% | -20.7% | +5.9% | -14.3% |
| 3M | -22.2% | +46.3% | -68.5% | -23.2% |
| 6M | -22.6% | +305.2% | -327.9% | -27.3% |
| YTD | -18.5% | +561.2% | -579.8% | -24.2% |
| 1Y | -13.9% | +772.1% | -786.0% | -20.3% |
| 3Y | +76.1% | +147.0% | -70.9% | +64.9% |
| All | +91.3% | -27.3% | +118.6% | +82.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling